Mezavant

Mesalazine, the active ingredient in Mezavant, is a 5-aminosalicylic acid (5-ASA) presented as an oral tablet for systemic use. It is used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, helping to reduce intestinal inflammation in adult patients.

GNH USA supplies Mezavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mezavant belongs to the 5‑ASA class and is employed in the management of inflammatory bowel disease.

Ulcerative colitis: reduces mucosal inflammation and induces remission. Crohn's disease: helps control intestinal inflammation in affected segments. Maintenance of remission in ulcerative colitis: sustains symptom‑free periods after induction therapy.

Mesalazine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or upset stomach. - Abdominal pain or cramps. - Headache. - Flatulence or bloating. - Rash or mild skin irritation. - Mild diarrhea.

Serious or Rare Side Effects: - Myocarditis or pericarditis. - Severe liver injury or hepatitis. - Blood dyscrasias such as neutropenia or agranulocytosis. - Acute pancreatitis. - Anaphylaxis or severe allergic reactions. - Interstitial nephritis or renal impairment.

Before initiating therapy, clinicians should consider several safety measures.

Renal function monitoring: assess baseline creatinine and periodic checks. Hepatic function monitoring: evaluate liver enzymes before and during treatment. Hypersensitivity assessment: discontinue if rash, fever, or eosinophilia develop. Severe disease caution: use with close monitoring in patients with extensive colitis. Sulfa allergy avoidance: avoid in individuals with known sulfonamide hypersensitivity. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mesalazine can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Azathioprine: increased risk of bone marrow suppression. - Warfarin: potentiation of anticoagulant effect, raising bleeding risk. - Methotrexate: heightened toxicity, especially hepatic.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy. - Allopurinol: may increase mesalazine plasma levels, requiring monitoring.